T3 Defense Inc. filed SEC Form 8-K: Other Events
8-K - T3 Defense Inc. (0001787518) (Filer)
- Director Davis Todd C bought $999,983 worth of shares (35,948 units at $27.82), increasing direct ownership by 90% to 75,834 units (SEC Form 4)
4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
- NeoGenomics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - NEOGENOMICS INC (0001077183) (Filer)
- Cipher Digital Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
8-K - Cipher Digital Inc. (0001819989) (Filer)
- Amendment: SEC Form 4 filed by CEO Gupta Shalabh K.
4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- Director Losada German Nicanor disposed of 3,900 units of Series A Shares and acquired 3,900 units of Series A Shares, decreasing direct ownership by 2% to 255,304 units (SEC Form 4)
4 - Vista Energy, S.A.B. de C.V. (0001762506) (Issuer)
- Teleflex Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
8-K - TELEFLEX INC (0000096943) (Filer)
- Amendment: SEC Form 4 filed by Director Kenkare-Mitra Sara
4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- SEC Form 4 filed by Director Maroun Richard E
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)
- Amendment: SEC Form 4 filed by Director Laumas Sandeep
4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- Amendment: SEC Form 4 filed by EVP, Pharmaceuticals and BD Gupta Pramod
4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- Amendment: SEC Form 4 filed by CFO Townsend John
4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- Nixxy Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
8-K - Nixxy, Inc. (0001462223) (Filer)
- PureCycle Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure
8-K - PureCycle Technologies, Inc. (0001830033) (Filer)
- SEC Form FWP filed by Canadian Imperial Bank of Commerce
FWP - CANADIAN IMPERIAL BANK OF COMMERCE /CAN/ (0001045520) (Subject)
- Amendment: SEC Form 4 filed by EVP, Corporate Strategy Jermasek Douglas
4/A - Unicycive Therapeutics, Inc. (0001766140) (Issuer)
- NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, announced today that it has commenced a private offering of $275 million aggregate principal amount of convertible senior notes due 2032 (the "notes") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In connection with this offering, NeoGenomics expects to grant the initial purchasers of the notes an option to purchase, for settlement within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $41.25 million agg
- SEC Form 4 filed by Director Hirmand Mohammad
4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)